NASDAQ:XAIR

Beyond Air Stock Forecast, Price & News

$5.51
+0.26 (+4.95 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.25
$5.53
50-Day Range
$4.72
$6.14
52-Week Range
$4.62
$7.96
Volume245,388 shs
Average Volume380,459 shs
Market Capitalization$112.90 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.56
30 days | 90 days | 365 days | Advanced Chart
Receive XAIR News and Ratings via Email

Sign-up to receive the latest news and ratings for Beyond Air and its competitors with MarketBeat's FREE daily newsletter.


Beyond Air logo

About Beyond Air

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

749th out of 2,099 stocks

Surgical & Medical Instruments Industry

67th out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Beyond Air (NASDAQ:XAIR) Frequently Asked Questions

Is Beyond Air a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beyond Air in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Beyond Air stock.
View analyst ratings for Beyond Air
or view top-rated stocks.

What stocks does MarketBeat like better than Beyond Air?

Wall Street analysts have given Beyond Air a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Beyond Air wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Beyond Air's next earnings date?

Beyond Air is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Beyond Air
.

How were Beyond Air's earnings last quarter?

Beyond Air, Inc. (NASDAQ:XAIR) posted its quarterly earnings results on Wednesday, June, 9th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.07. Beyond Air had a negative trailing twelve-month return on equity of 133.04% and a negative net margin of 2,617.28%.
View Beyond Air's earnings history
.

How has Beyond Air's stock been impacted by Coronavirus (COVID-19)?

Beyond Air's stock was trading at $5.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XAIR stock has increased by 3.6% and is now trading at $5.51.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for XAIR?

3 equities research analysts have issued 12-month price objectives for Beyond Air's shares. Their forecasts range from $9.00 to $12.00. On average, they anticipate Beyond Air's stock price to reach $11.00 in the next year. This suggests a possible upside of 99.6% from the stock's current price.
View analysts' price targets for Beyond Air
or view top-rated stocks among Wall Street analysts.

Who are Beyond Air's key executives?

Beyond Air's management team includes the following people:
  • Mr. Steven Adam Lisi, CEO & Chairman (Age 50, Pay $450k)
  • Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 47, Pay $400k)
  • Mr. Douglas J. Beck CPA, CPA, Chief Financial Officer (Age 60, Pay $250k)
  • Mr. Adam Newman, Chief Legal Officer & Gen. Counsel
  • Mr. Duncan Fatkin, Chief Commercial Officer
  • Ms. Maria Yonkoski, Head of Investor Relations
  • Dr. Giora Davidai M.D., Chief Medical Officer
  • Mr. Ali Ardakani, Sr. VP of Device & Bus. Devel.
  • Mr. Michael A. Gaul, Sr. VP of Operations (Age 66)
  • Hila Confino Ph.D., Research Project Mang.

Who are some of Beyond Air's key competitors?

What other stocks do shareholders of Beyond Air own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beyond Air investors own include OPKO Health (OPK), NVIDIA (NVDA), Pfizer (PFE), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Enphase Energy (ENPH), General Motors (GM), Livongo Health (LVGO), Main Street Capital (MAIN) and Ollie's Bargain Outlet (OLLI).

What is Beyond Air's stock symbol?

Beyond Air trades on the NASDAQ under the ticker symbol "XAIR."

Who are Beyond Air's major shareholders?

Beyond Air's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.67%), Geode Capital Management LLC (1.19%), Northern Trust Corp (1.02%), Flagship Harbor Advisors LLC (0.58%), Ameriprise Financial Inc. (0.50%) and Squarepoint Ops LLC (0.23%). Company insiders that own Beyond Air stock include Amir Avniel, Douglas Beck, Robert Carey, Ron Bentsur and Steven A Lisi.
View institutional ownership trends for Beyond Air
.

Which major investors are selling Beyond Air stock?

XAIR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ameriprise Financial Inc., Northern Trust Corp, and Baldwin Brothers Inc. MA. Company insiders that have sold Beyond Air company stock in the last year include Amir Avniel, and Ron Bentsur.
View insider buying and selling activity for Beyond Air
or view top insider-selling stocks.

Which major investors are buying Beyond Air stock?

XAIR stock was bought by a variety of institutional investors in the last quarter, including Flagship Harbor Advisors LLC, BlackRock Inc., Geode Capital Management LLC, Virtu Financial LLC, GSA Capital Partners LLP, Goldman Sachs Group Inc., Squarepoint Ops LLC, and Millennium Management LLC. Company insiders that have bought Beyond Air stock in the last two years include Amir Avniel, Douglas Beck, Robert Carey, and Steven A Lisi.
View insider buying and selling activity for Beyond Air
or or view top insider-buying stocks.

How do I buy shares of Beyond Air?

Shares of XAIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Beyond Air's stock price today?

One share of XAIR stock can currently be purchased for approximately $5.51.

How much money does Beyond Air make?

Beyond Air has a market capitalization of $112.90 million and generates $870,000.00 in revenue each year. The company earns $-19,940,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does Beyond Air have?

Beyond Air employs 23 workers across the globe.

What is Beyond Air's official website?

The official website for Beyond Air is www.ait-pharm.com.

Where are Beyond Air's headquarters?

Beyond Air is headquartered at 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530.

How can I contact Beyond Air?

Beyond Air's mailing address is 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530. The company can be reached via phone at 516-665-8200.


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.